1. Dhar A, Haboubi HN, Attwood SE, Auth MKH, Dunn JM, Sweis R, Morris D, Epstein J, Novelli MR, Hunter H, Cordell A, Hall S, Hayat JO, Kapur K, Moore AR, Read C, Sami SS, Turner PJ, Trudgill NJ. British Society of Gastroenterology (BSG) and British Society of Paediatric Gastroenterology, Hepatology and Nutrition (BSPGHAN) joint consensus guidelines on the diagnosis and management of eosinophilic oesophagitis in children and adults. Gut. 2022 Aug; 71(8): 1459 - 1487 https://doi.org/10.1136/gutjnl-2022-327326.

2. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О., Трухманов А.С., Шептулин А.А. Клинические рекомендации по диагностике и лечению эозинофильного эзофагита. М., 2013. [Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O., Trukhmanov A.S., Sheptulin A.A. Klinicheskie rekomendatsii po diagnostike i lecheniyu eozinofil'nogo ezofagita. M., 2013. (In Russ.)]

3. Эозинофильный эзофагит / В. О. Кайбышева, Л. М. Михалева, Е. Д. Федоров [и др.]. - Переработанное и дополненное издание. - Москва: Издательство "Медиа Сфера", 2024. - 180 с. - ISBN 978-5-89084-077-6. - EDN LYSCJD.

4. Диагностика и лечение эозинофильного эзофагита: Методические рекомендации / В. О. Кайбышева, О. М. Драпкина, И. В. Маев [и др.]. - Москва: ООО Силицея-Полиграф, 2024. - 58 с. - ISBN 978-5-605-25985-5. - DOI 10.15829/ROPNIZ-k7-2024. - EDN RMANOJ.

5. Кайбышева В.О., Михалева Л.М., Никонов Е.Л., Шаповальянц С.Г. Эпидемиология, этиология и патогенез эозинофильного эзофагита. Новейшие данные. Доказательная гастроэнтерология. 2019; 8(2): 5072. Kaibysheva VO, Mikhaleva LM, Nikonov EL, Shapoval'yants SG. Epidemiology, etiology and pathogenesis of eosinophilic esophagitis. The latest data. Russian Journal of Evidence-Based Gastroenterology. 2019; 8(2): 5072. (In Russ., In Engl.). https://doi.org/10.17116/dokgastro2019802150

6. Arias A, Perez-Martinez I, Tenias JM, Lucendo AJ. Systematic review with meta- analysis: the incidence and prevalence of eosinophilic oesophagitis in children and adults in population-based studies. Aliment Pharmacol Ther 2016; 43: 3 - 15. https://doi.org/10.1111/apt.13441

7. van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Rapidly increasing incidence of eosinophilic esophagitis in a large cohort. Neurogastroenterol Motil 2013; 25: 47 - 5. https://doi.org/10.1111/nmo.12009

8. Warners M, de Rooij WE, Van Rhijn BD, Verheij J, Smout AJ, Bredenoord AJ. Large Increase in Incidence of Eosinophilc Esophagitis Over the Last 20 Years in the Netherlands: Results from a Nationwide Pathology Database. Gastroenterology 2017; 152: 862 - 863. https://doi.org/10.1016/S0016-5085(17) 32964-5

9. Noel RJ, Putnam PE, Rothenberg ME. Eosinophilic esophagitis. N Engl J Med 2004; 351: 940 - 1.

10. Hahn JW, Lee K, Shin JI, Cho SH, Turner S, Shin JU, , Koyanagi A, Jacob L, Smith L, Fond G, Boyer L, Lee SW, Kwon R, Kim S, Shin YH, Rhee SY, Moon JS, Ko JS, Yon DK, Papadopoulos NG. Global Incidence and Prevalence of Eosinophilic Esophagitis, 1976 - 2022: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023 Dec; 21(13): 3270 - 3284. e77. doi: 10.1016/j.cgh.2023.06.005.

11. Prasad GA, Alexander JA, Schleck CD, Zinsmeister AR, Smyrk TC, Elias RM, Locke GR, Talley NJ. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol 2009; 7: 1055 - 61. https://doi.org/10.1016/j.cgh.2009.06.023

12. Syed AA, Andrews CN, Shaffer E, Urbanski SJ, Beck P, Storr M. The rising incidence of eosinophilic oesophagitis is associated with increasing biopsy rates: a population-based study. Aliment Pharmacol Ther 2012; 36: 950 - 8. https://doi.org/10.1111/apt.12053

13. Dellon ES, Erichsen R, Baron JA, Shaheen NJ, Vyberg M, Sorensen HT, Pedersen L. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther 2015; 41: 662 - 70. https://doi.org/10.1111/apt.13129

14. Giriens B, Yan P, Safroneeva E, Zwahlen M, Reinhard A, Nydegger A, Vavricka S, Sempoux C, Straumann A, Schoepfer AM. Escalating incidence of eosinophilic esophagitis in Canton of Vaud, Switzerland, 1993 - 2013: a population-based study. Allergy 2015; 70: 1633 - 9. https://doi.org/10.1111/all.12733

15. Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol 2005; 115: 418 - 9. https://doi.org/10.1016/j.jaci.2004.11.006

16. Dellon ES, Liacouras CA, Molina-Infante J et al. Updated International Consensus Diagnos-tic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroen-terology. 2018 https://doi.org/10.1053/j.gastro.2018.07.009.

17. Straumann A, Katzka DA. Diagnosis and Treatment of Eosinophilic Esophagitis. Gastroen-terology. 2018 Jan; 154(2): 346 - 359. https://doi.org/10.1053/j.gastro.2017.05.066

18. Lucendo AJ, Friginal-Ruiz AB, Rodriguez B. Boerhaave's syndrome as the primary manifes-tation of adult eosinophilic esophagitis. Two case reports and a review of the literature. Dis Esophagus 2011; 24: E11 - 5. https://doi.org/10.1111/j.1442-2050.2010.01167.x

19. Straumann A, Bussmann C, Zuber M, et al. Eosinophilic esophagitis: analysis of food impac-tion and perforation in 251 adolescent and adult patients. Clin Gastroenterol Hepatol 2008; 6: 598 - 600. https://doi.org/10.1016/j.cgh.2008.02.003

20. Jackson WE, Mehendiratta V, Palazzo J, et al. Boerhaave's syndrome as an initial presenta-tion of eosinophilic esophagitis: a case series. Ann Gastroenterol 2013; 26: 166 - 169.

21. Lucendo AJ, Molina-Infante J, , von Arnim U, Bredenoord AJ, Bussmann C, Amil Dias J, Bove M, , Larsson H, Miehlke S, Papadopoulou A, , Ravelli A, Ronkainen J, Santander C, Schoepfer AM, Storr MA, Terreehorst I, Straumann A, Attwood SE. Guidelines on eosinophilic esophagitis: evidence-based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterol J. 2017; 5(3): 335 - 358. https://doi.org/10.1177/2050640616689525

22. Ивашкин В.Т., Баранская Е.К., Кайбышева В.О., Иванова Е.В., Федоров Е.Д. Эозинофильный эзофагит: обзор литературы и описание собственного наблюдени. РЖГГК; 2012: 1. 71 - 81. [Ivashkin V.T., Baranskaya E.K., Kaibysheva V.O., Ivanova E.V., Fedorov E.D. Eozinofil'nyi ezofagit: obzor literatury i opisanie sobstvennogo nablyudeniya // RZhGGK. 2012: 1. 71 - 81. (In Russ.)]

23. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distinguish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepatol 2009; 7: 1305 - 1313.

24. Remedios M, Campbell C, Jones DM, et al. Eosinophilic esophagitis in adults: clinical, endoscopic, histologic findings, and response to treatment with fluticasone propionate. Gastrointest Endosc 2006; 63: 3 - 12.

25. Croese J, Fairley SK, Masson JW, et al. Clinical and endoscopic features of eosinophilic esophagitis in adults. Gastrointest Endosc 2003; 58: 516 - 522.

26. Kahn J, Bussmann C, Beglinger C, et al. Exercise-induced chest pain: an atypical manifestation of eosinophilic esophagitis. Am J Med 2015; 128: 196 - 199. https://doi.org/10.1016/j.amjmed.2014.08.007

27. Gonsalves N, Policarpio-Nicolas M, Zhang Q, et al. Histopathologic variability and endoscopic correlates in adults with eosinophilic esophagitis. Gastrointest Endosc 2006; 64: 313 - 319.

28. Shah A, Kagalwalla AF, Gonsalves N, et al. Histopathologic variability in children with eosinophilic esophagitis. Am J Gastroenterol 2009; 104: 716 - 721.

29. Peery AF, Cao H, Dominik R, et al. Variable reliability of endoscopic findings with white-light and narrow-band imaging for patients with suspected eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011; 9: 475 - 480. https://doi.org/10.1016/j.cgh.2011.02.026

30. Dellon ES, Speck O, Woodward K. The patchy nature of esophageal eosinophilia in eosinophilic esophagitis: Insights from pathology samples from a clinical trial. Gastroenterology 2012; 142(Suppl): Su-1129. https://doi.org/10.1016/S0016-5085(12) 61626 - 6

31. DeBrosse CW, Collins MH, Buckmeier Butz BK, et al. Identification, epidemiology, and chronicity of pediatric esophageal eosinophilia, 1982 - 1999. J Allergy Clin Immunol 2010; 126: 112 - 9.

32. Kim HP, Vance RB, Shaheen NJ, et al. The prevalence and diagnostic utility of endoscopic features of eosinophilic esophagitis: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 988 - 996. https://doi.org/10.1016/j.cgh.2012.04.019

33. Hirano I, Moy N, Heckman MG, et al. Endoscopic assessment of the oesophageal features of eosinophilic oesophagitis: validation of a novel classification and grading system. Gut 2013; 62: 489 - 95. https://doi.org/10.1136/gutjnl-2011-301817

34. Dellon ES, Gibbs WB, Fritchie KJ, et al. Clinical, endoscopic, and histologic findings distin-guish eosinophilic esophagitis from gastroesophageal reflux disease. Clin Gastroenterol Hepa-tol 2009; 7: 1305 - 13; https://doi.org/10.1016/j.cgh.2009.08.030

35. Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013; 145: 1230 - 2.

36. Lipka S, Kumar A, Richter JE. Impact of diagnostic delay and other risk factors on eosinophilic esophagitis phenotype and esophageal diameter. J Clin Gastroenterol 2016; 50: 134 - 40.

37. Warners MJ, Oude Nijhuis RAB, de Wijkerslooth LRH, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol 2018; 113: 836 - 44.

38. Peterson KA, Byrne KR, Vinson LA, et al. Elemental diet induces histologic response in adult eosinophilic esophagitis. Am J Gastroenterol 2013; 108: 759 - 766. https://doi.org/10.1038/ajg.2012.468

39. Arias A, Gonzalez-Cervera J, Tenias JM, et al. Efficacy of dietary interventions for inducing histologic remission in patients with eosinophilic esophagitis: a systematic review and meta-analysis. Gastroenterology 2014; 146: 1639 - 1648. https://doi.org/10.1053/j.gastro.2014.02.006

40. Spergel JM, Beausoleil JL, Mascarenhas M, et al. The use of skin prick tests and patch tests to identify causative foods in eosinophilic esophagitis. J Allergy Clin Immunol 2002; 109: 363 - 368.

41. Spergel JM, Brown-Whitehorn TF, Cianferoni A, et al. Identification of causative foods in children with eosinophilic esophagitis treated with an elimination diet. J Allergy Clin Immunol 2012; 130: 461 - 467. https://doi.org/10.1016/j.jaci.2012.05.021

42. Kagalwalla AF, Shah A, Ritz S, et al. Cow's milk protein-induced eosinophilic esophagitis in a child with gluten-sensitive enteropathy. J Pediatr Gastroenterol Nutr 2007; 44: 386 - 388. https://doi.org/10.1097/01.mpg.0000243430.32087.5c

43. Wolf WA, Jerath MR, Sperry SLW, et al. Dietary elimination therapy is an effective option for adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2014; 12: 1272 - 1279. https://doi.org/10.1016/j.cgh.2013.12.034

44. Molina-Infante J, Martin-Noguerol E, Alvarado-Arenas M, et al. Selective elimination diet based on skin testing has suboptimal efficacy for adult eosinophilic esophagitis. J Allergy Clin Immunol 2012; 130: 1200 - 1202. https://doi.org/10.1016/j.jaci.2012.06.027

45. Kagalwalla AF, Sentongo TA, Ritz S, et al. Effect of six-food elimination diet on clinical and histologic outcomes in eosinophilic esophagitis. Clin Gastroenterol Hepatol 2006; 4: 1097 - 1102.

46. Henderson CJ, Abonia JP, King EC, et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012; 129: 1570 - 1578. https://doi.org/10.1016/j.jaci.2012.03.023

47. Kagalwalla AF, Shah A, Li BUK, et al. Identification of specific foods responsible for inflammation in children with eosinophilic esophagitis successfully treated with empiric elimination diet. J Pediatr Gastroenterol Nutr 2011; 53: 145 - 149. https://doi.org/10.1097/MPG.0b013e31821cf503

48. Molina-Infante J, Arias A, Barrio J, et al. Four-food group elimination diet for adult eosinophilic esophagitis: A prospective multicenter study. J Allergy Clin Immunol 2014; 134: 1093 - 1099. https://doi.org/10.1016/j.jaci.2014.07.023

49. Philpott H, Nandurkar S, Royce SG, et al. Allergy tests do not predict food triggers in adult patients with eosinophilic oesophagitis. A comprehensive prospective study using five modalities. Aliment Pharmacol Ther 2016; 44: 223 - 233. https://doi.org/10.1111/apt.13676

50. Kagalwalla AF, Amsden K, Shah A, et al. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2012; 55: 711 - 716. https://doi.org/10.1097/MPG.0b013e318268da40

51. Kruszewski PG, Russo JM, Franciosi JP, et al. Prospective, comparative effectiveness trial of cow's milk elimination and swallowed fluticasone for pediatric eosinophilic esophagitis. Dis Esophagus 2016; 29: 377 - 384. https://doi.org/10.1111/dote.12339

52. Molina-Infante J, , Alcedo J, Garcia-Romero R, Casabona-Frances S, Prieto-Garcia A, Modolell I, Gonzalez-Cordero PL, Perez-Martinez I, Martin-Lorente JL, Guarner-Argente C, Masiques ML, Vila-Miravet V, Garcia-Puig R, Savarino E, Sanchez-Vegazo CT, Santander C, Lucendo AJ. Step-up empiric elimination diet for pediatric and adult eosinophilic esophagitis: The 2 - 4 - 6 study. J Allergy Clin Immunol. 2018; 141(4): 1365 - 1372. https://doi.org/10.1016/j.jaci.2017.08.038

53. Gonsalves N, Yang G-Y, Doerfler B, et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012; 142: 1451 - 1455. https://doi.org/10.1053/j.gastro.2012.03.001

54. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013;131:797 - 804. https://doi.org/10.1016/j.jaci.2012.12.664

55. Moawad FJ, Veerappan GR, Dias JA, et al. Randomized controlled trial comparing aeroso-lized swallowed fluticasone to esomeprazole for esophageal eosinophilia. Am J Gastroenterol 2013; 108: 366 - 372. https://doi.org/10.1038/ajg.2012.443

56. Peterson KA, Thomas KL, Hilden K, et al. Comparison of esomeprazole to aerosolized, swal-lowed fluticasone for eosinophilic esophagitis. Dig Dis Sci 2010; 55: 1313 - 1319. https://doi.org/10.1007/s10620-009-0859-4

57. Cheng E, Zhang X, Huo X, Yu C, Zhang Q, Wang DH, Spechler SJ, Souza RF. Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD. Gut. 2013 Jun; 62(6): 824 - 32. https://doi.org/10.1136/gutjnl-2012-302250.

58. Ngo P, Furuta GT, Antonioli DA, et al. Eosinophils in the esophagus--peptic or allergic eo-sinophilic esophagitis? Case series of three patients with esophageal eosinophilia. Am J Gas-troenterol 2006; 101: 1666 - 1670.

59. Dranove JE, Horn DS, Davis MA, et al. Predictors of response to proton pump inhibitor ther-apy among children with significant esophageal eosinophilia. J Pediatr 2009; 154: 96 - 100. https://doi.org/10.1016/j.jpeds.2008.07.042

60. Molina-Infante J, Ferrando-Lamana L, Ripoll C, et al. Esophageal eosinophilic infiltration re-sponds to proton pump inhibition in most adults. Clin Gastroenterol Hepatol 2011; 9: 110 - 117. https://doi.org/10.1016/j.cgh.2010.09.019

61. Gutierrez-Junquera C, Fernandez-Fernandez S, Cilleruelo ML, et al. High prevalence of re-sponse to proton-pump inhibitor treatment in children with esophageal eosinophilia. J Pediatr Gastroenterol Nutr 2016; 62: 704 - 710. https://doi.org/10.1097/MPG.0000000000001019

62. Lucendo AJ, Arias A, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a sys-tematic review and meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 13 - 22. https://doi.org/10.1016/j.cgh.2015.07.041

63. Cheng E, Zhang X, Wilson KS, Wang DH, Park JY, Huo X, Yu C, Zhang Q, Spechler SJ, Souza RF. JAK-STAT6 Pathway Inhibitors Block Eotaxin-3 Secretion by Epithelial Cells and Fibroblasts from Esophageal Eosinophilia Patients: Promising Agents to Improve In-flammation and Prevent Fibrosis in EoE. PLoS One. 2016 Jun 16; 11(6): e0157376. https://doi.org/10.1371/journal.pone.0157376.

64. Dellon ES, Liacouras CA. Advances in clinical management of eosinophilic esophagitis. Gas-troenterology 2014; 147: 1238 - 1254. https://doi.org/10.1053/j.gastro.2014.07.055

65. Molina-Infante J, Rodriguez-Sanchez J, Martinek J, et al. Long-term loss of response in pro-ton pump inhibitor-responsive esophageal eosinophilia is uncommon and influenced by CYP2C19 genotype and rhinoconjunctivitis. Am J Gastroenterol 2015; 110: 1567 - 1575. https://doi.org/10.1038/ajg.2015.314

66. Schaefer ET, Fitzgerald JF, Molleston JP, et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008; 6: 165 - 173.

67. Alexander JA, Jung KW, Arora AS, et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012; 10: 742 - 749. https://doi.org/10.1016/j.cgh.2012.03.018

68. Gupta SK, Vitanza JM, Collins MH. Efficacy and safety of oral budesonide suspension in pediatric patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2015; 13: 66 - 76. https://doi.org/10.1016/j.cgh.2014.05.021

69. Dohil R, Newbury R, Fox L, et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010; 139: 418 - 429. https://doi.org/10.1053/j.gastro.2010.05.001

70. Konikoff MR, Noel RJ, Blanchard C, et al. A randomized, double-blind, placebo- controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006; 131: 1381 - 1391.

71. Dellon ES, Sheikh A, Speck O, et al. Viscous topical is more effective than nebulized steroid therapy for patients with eosinophilic esophagitis. Gastroenterology 2012; 143: 321 - 324. https://doi.org/10.1053/j.gastro.2012.04.049

72. Butz BK, Wen T, Gleich GJ, et al. Efficacy, dose reduction, and resistance to high-dose fluticasone in patients with eosinophilic esophagitis. Gastroenterology 2014; 147: 324 - 333. https://doi.org/10.1053/j.gastro.2014.04.019

73. Miehlke S, Hruz P, Vieth M, et al. A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis. Gut 2016; 65: 390 - 399. https://doi.org/10.1136/gutjnl-2014-308815

74. Tan N Di, Xiao YL, Chen MH. Steroids therapy for eosinophilic esophagitis: Systematic review and meta-analysis. J Dig Dis 2015; 16: 431 - 442. https://doi.org/10.1111/1751-2980.12265

75. Sawas T, Dhalla S, Sayyar M, et al. Systematic review with meta-analysis: pharmacological interventions for eosinophilic oesophagitis. Aliment Pharmacol Ther 2015; 41: 797 - 806. https://doi.org/10.1111/apt.13147

76. Murali AR, Gupta A, Attar BM, et al. Topical steroids in eosinophilic esophagitis: systematic review and meta-analysis of placebo controlled randomized clinical trials. J Gastroenterol Hepatol 2015; 31: 1111 - 1119. https://doi.org/10.1111/jgh.13281

77. Chuang M-YA, Chinnaratha MA, Hancock DG, et al. Topical steroid therapy for the treatment of eosinophilic esophagitis (EoE): a systematic review and meta- analysis. Clin Transl Gastroenterol 2015; 6: e82. https://doi.org/10.1038/ctg.2015.9

78. Straumann A, Conus S, Degen L, et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011; 9: 400 - 409. https://doi.org/10.1016/j.cgh.2011.01.017

79. Philla KQ, Min SB, Hefner JN, et al. Swallowed glucocorticoid therapy for eosinophilic esophagitis in children does not suppress adrenal function. J Pediatr Endocrinol Metab 2015; 28: 1101 - 1106. https://doi.org/10.1515/jpem-2014-0260

80. Golekoh MC, Hornung LN, Mukkada VA, et al. Adrenal insufficiency after chronic swallowed glucocorticoid therapy for eosinophilic esophagitis. J Pediatr 2016; 170: 240 - 245. https://doi.org/10.1016/j.jpeds.2015.11.026

81. Harel S, Hursh BE, Chan ES, et al. Adrenal suppression in children treated with oral viscous budesonide for eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2015; 61: 190 - 193. https://doi.org/10.1097/MPG.0000000000000848

82. Moawad FJ, Cheatham JG, DeZee KJ. Meta-analysis: the safety and efficacy of dilation in eosinophilic oesophagitis. Aliment Pharmacol Ther 2013; 38: 713 - 720. https://doi.org/10.1111/apt.12438

83. Netzer P, Gschossmann JM, Straumann A, et al. Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. Eur J Gastroenterol Hepatol 2007; 19: 865 - 869.

84. Abonia JP, Blanchard C, Butz BB, et al. Involvement of mast cells in eosinophilic esophagitis. J Allergy Clin Immunol 2010; 126: 140 - 149. https://doi.org/10.1016/j.jaci.2010.04.009

85. Arias A, Lucendo AJ, Martinez-Fernandez P, et al. Dietary treatment modulates mast cell phenotype, density, and activity in adult eosinophilic oesophagitis. Clin Exp Allergy 2016; 46: 78 - 91. https://doi.org/10.1111/cea.12504

86. Liacouras CA, Spergel JM, Ruchelli E, et al. Eosinophilic esophagitis: A 10-year experience in 381 children. Clin Gastroenterol Hepatol 2005; 3: 1198 - 1206.

87. Attwood SEA, Lewis CJ, Bronder CS, et al. Eosinophilic oesophagitis: a novel treatment using Montelukast. Gut 2003; 52: 181 - 185.

88. Stumphy J, Al-Zubeidi D, Guerin L, Mitros F, Rahhal R. Observations on use of montelukast in pediatric eosinophilic esophagitis: insights for the future. Dis Esophagus. Australia; 2011; 24(4): 229 - 34. https://doi.org/10.1111/j.1442-2050.2010.01134.x

89. Alexander JA, Ravi K, Enders FT, Geno DM, Kryzer LA, Mara KC, Smyrk TC, Katzka DA. Montelukast Does not Maintain Symptom Remission After Topical Steroid Therapy for Eosinophilic Esophagitis. Clin Gastroenterol Hepatol. 2017; 15(2): 214 - 221. e2. https://doi.org/10.1016/j.cgh.2016.09.013

90. Lucendo AJ, De Rezende LC, Jimenez-Contreras S, et al. Montelukast was inefficient in maintaining steroid-induced remission in adult eosinophilic esophagitis. Dig Dis Sci 2011; 56: 3551 - 3558. https://doi.org/10.1007/s10620-011-1775-y

91. Straumann A, Bauer M, Fischer B, Blaser K, Simon H-U. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol. 2001; 108(6): 954 - 61

92. O'Byrne PM, Inman MD, Parameswaran K. The trials and tribulations of IL-5, eosinophils, and allergic asthma. J Allergy Clin Immunol. 2001; 108(4): 503 - 8.

93. Mishra A, Rothenberg ME. Intratracheal IL-13 induces eosinophilic esophagitis by an IL-5, eotaxin-1, and STAT6-dependent mechanism. Gastroenterology. 2003; 125(5): 1419 - 27.

94. Straumann A, Conus S, Grzonka P, et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo- controlled, double-blind trial. Gut 2010; 59: 21 - 30. https://doi.org/10.1136/gut.2009.178558

95. Assa'ad AH, Gupta SK, Collins MH, et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011; 141: 1593 - 1604. https://doi.org/10.1053/j.gastro.2011.07.044

96. Spergel JM, Rothenberg ME, Collins MH, et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012; 129: 456 - 463. https://doi.org/10.1016/j.jaci.2011.11.044

97. Zuo L, Fulkerson PC, Finkelman FD, Mingler M, Fischetti CA, et al. IL-13 induces esophageal remodeling and gene expression by an eosinophil-independent, IL-13R 2-inhibited pathway. J Immunol. 2010; 185(1): 660 - 69. https://doi.org/10.4049/jimmunol.1000471

98. Doran E, Cai F, Holweg CTJ, Wong K, Brumm J, Arron JR. Interleukin-13 in Asthma and Other Eosinophilic Disorders. Front Med (Lausanne). 2017 Sep 19; 4: 139. https://doi.org/110.3389/fmed.2017.00139

99. Davis BP, Stucke EM, Khorki ME, et al. Eosinophilic esophagitis-linked calpain 14 is an IL-13- induced protease that mediates esophageal epithelial barrier impairment. JCI Insight 2016; 1: 86355. https://doi.org/10.1172/jci.insight.86355

100. Rothenberg ME, Wen T, Greenberg A, et al. Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. J Allergy Clin Immunol 2015; 135: 500 - 7. https://doi.org/10.1016/j.jaci.2014.07.049.

101. Blanchard C, Mishra A, Saito-Akei H, Monk P, Anderson I, Rothenberg ME. Inhibition of human interleukin-13-induced respiratory and oesophageal inflammation by anti-human-interleukin-13 antibody (CAT-354). Clin Exp Allergy. 2005; 35(8): 1096 - 103.

102. Spergel BL, Ruffner MA, Godwin BC et al. Improvement in eosinophilic esophagitis when using dupilumab for other indications or compassionate use. Ann Allergy Asthma Immunol. 2022 May; 128(5): 589 - 593. doi: 10.1016/j.anai.2022.01.019. Epub 2022 Jan 25. PMID: 3508581

103. Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoEconnect registry. Aliment Pharmacol Ther 2020; 52: 798 - 807.

104. Lucendo AJ, Miehlke S, Schlag C, et al. Efficacy of budesonide orodispersible tablets as induction therapy for eosinophilic esophagitis in a randomized placebo-controlled trial. Gastroenterology 2019; 157: 74 - 86.

105. Straumann A, Lucendo AJ, Miehlke S, et al. Budesonide Orodispersible tablets maintain remission in a randomized, placebo-controlled trial of patients with eosinophilic esophagitis. Gastroenterology 2020; 159: 1672 - 85.

106. Валитова Э.Р., Эмбутниекс Ю.В., Березина О.И., Бордин Д.С., Хомерики С.Г., Казакова С.С. Эозинофильный эзофагит. Экспериментальная и клиническая гастроэнтерология. 2018; (10): 115 - 119.

107. Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients with Eosinophilic Esophagitis (EoE). Электронный ресурс: https://clinicaltrials.gov/ct2/show/NCT03633617.

108. Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients with Active Eosinophilic Esophagitis (EoE) (EoE KIDS). Электронный ресурс: https://clinicaltrials.gov/ct2/show/NCT04394351

109. Dellon ES, Khoury P, Muir AB, Liacouras CA, Safroneeva E, Atkins D, Collins MH, Gonsalves N, Falk GW, Spergel JM, Hirano I, Chehade M, Schoepfer AM, Menard-Katcher C, Katzka DA, Bonis PA, Bredenoord AJ, Geng B, Jensen ET, Pesek RD, Feuerstadt P, Gupta SK, Lucendo AJ, Genta RM, Hiremath G, McGowan EC, Moawad FJ, Peterson KA, Rothenberg ME, Straumann A, Furuta GT, Aceves SS. A Clinical Severity Index for Eosinophilic Esophagitis: Development, Consensus, and Future Directions. Gastroenterology. 2022 Jul; 163(1): 59 - 76. doi: 10.1053/j.gastro.2022.03.025. Epub 2022 May 20. PMID: 35606197; PMCID: PMC9233087.

110. Gomez Torrijos E, Gonzalez-Mendiola R, Alvarado M, Avila R, Prieto-Garcia A, Valbuena T, Borja J, Infante S, Lopez MP, Marchan E, Prieto P, Moro M, Rosado A, Saiz V, Somoza ML, Uriel O, Vazquez A, Mur P, Poza-Guedes P, Bartra J. Eosinophilic Esophagitis: Review and Update. Front Med (Lausanne). 2018 Oct 9; 5: 247. doi: 10.3389/fmed.2018.00247.

111. Barni S, Arasi S, Mastrorilli C, Pecoraro L, Giovannini M, Mori F, Liotti L, Saretta F, Castagnoli R, Caminiti L, Cianferoni A, Novembre E. Pediatric eosinophilic esophagitis: a review for the clinician. Ital J Pediatr. 2021 Nov 22; 47(1): 230. doi: 10.1186/s13052-021-01178-2

112. Young E., Philpott H. Pathophysiology of Dysphagia in Eosinophilic Esophagitis: Causes, Consequences, and Management. Dig Dis Sci. 2022; 67(4): 1101 - 1115

113. Shoda T, Wen T, Aceves SS, Abonia JP, Atkins D, Bonis PA, Caldwell JM, Capocelli KE, Carpenter CL, Collins MH, Dellon ES, Eby MD, Gonsalves N, Gupta SK, Falk GW, Hirano I, Menard-Katcher P, Kuhl JT, Krischer JP, Leung J, Mukkada VA, Spergel JM, Trimarchi MP, Yang GY, Zimmermann N, Furuta GT, Rothenberg ME; Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). Eosinophilic oesophagitis endotype classification by molecular, clinical, and histopathological analyses: a cross-sectional study. Lancet Gastroenterol Hepatol. 2018 Jul; 3(7): 477 - 488. doi: 10.1016/S2468-1253(18) 30096 - 7.

114. Keely S, Talley NJ. Endophenotyping eosinophilic oesophagitis: a new era for management? Lancet Gastroenterol Hepatol. 2018 Jul; 3(7): 449 - 450. doi: 10.1016/S2468-1253(18) 30134-1.

115. Straumann A, Aceves SS, Blanchard C, Collins MH, Furuta GT, Hirano I. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy. 2012 Apr. 67(4): 477 - 90

116. Dellon ES, Gonsalves N, Hirano I, Furuta GT, Liacouras CA, Katzka DA. ACG clinical guideline: Evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). The American journal of gastroenterology. 2013

117. Hirano I. Role of advanced diagnostics for eosinophilic esophagitis. Dig Dis. 2014; 32(1 - 2): 78 - 83.

118. Warners MJ, Hindryckx P, Levesque BG, Parker CE, Shackelton LM, Khanna R, Sandborn WJ, D'Haens GR, Feagan BG, Bredenoord AJ, Jairath V. Systematic Review: Disease Activity Indices in Eosinophilic Esophagitis. Am J Gastroenterol. 2017 Nov; 112(11): 1658 - 1669].

119. Gentile N, Katzka D, Ravi K, et al. Esophageal narrowing is common and frequently under-appreciated at endoscopy in patients with esophageal eosinophilia. Aliment Pharmacol Ther. 2014; 40: 1333 - 1340.

120. Nelson MJ, Miller FH, Moy N, et al. Comparison of endoscopy and radiographic imaging for detection of esophageal inflammation and remodeling in adults with eosinophilic esophagitis. Gastrointest Endosc. 2018; 87: 962 - 968.

121. Hassan M, Aceves S, Dohil R, et al. Esophageal compliance quantifies epithelial remodeling in pediatric patients with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2019; 68: 559 - 565.

122. Collins MH, Martin LJ, Alexander ES, et al. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017; 30: 1 - 8.

123. Muir A, Falk GW. Eosinophilic Esophagitis: A Review. JAMA. 2021 Oct 5; 326(13): 1310 - 1318. doi: 10.1001/jama.2021.14920

124. Campora M, Mastracci L, Carlin L, Unti E, Parente P, Fassan M, Ferro J, Errico ME, Donofrio V, Grillo F. Pathologist's approach to paediatric and neonatal eosinophilic gastrointestinal disorders. Pathologica. 2022 Feb; 114(1): 79 - 88

125. Collins MH, Martin LJ, Alexander ES, Boyd JT, Sheridan R, He H, Pentiuk S, Putnam PE, Abonia JP, Mukkada VA, Franciosi JP, Rothenberg ME. Newly developed and validated eosinophilic esophagitis histology scoring system and evidence that it outperforms peak eosinophil count for disease diagnosis and monitoring. Dis Esophagus. 2017 Feb 1; 30(3): 1 - 8. doi: 10.1111/dote.12470. PMID: 26857345; PMCID: PMC5373936.

126. Zand Irani M, Talley NJ, Ronkainen J, Aro P, Andreasson A, Agreus L, Vieth M, Jones MP, Walker MM. Neutrophils, eosinophils, and intraepithelial lymphocytes in the squamous esophagus in subjects with and without gastroesophageal reflux symptoms. Hum Pathol. 2021 Sep; 115: 112 - 122.

127. Gentile N, Katzka D, Ravi K, Trenkner S, Enders F, Killian J, Kryzer L, Talley NJ, Alexander J. Oesophageal narrowing is common and frequently under-appreciated at endoscopy in patients with oesophageal eosinophilia. Aliment Pharmacol Ther. 2014 Dec; 40(11 - 12): 1333 - 40. doi: 10.1111/apt.12977.

128. Binkovitz LA, Lorenz EA, Di Lorenzo C, Kahwash S. Pediatric eosinophilic esophagitis: radiologic findings with pathologic correlation. Pediatr Radiol. 2010 May; 40(5): 714 - 9. doi: 10.1007/s00247-009-1484-2.

129. Gonzalez Ayerbe JI, Hauser B, Salvatore S, Vandenplas Y. Diagnosis and Management of Gastroesophageal Reflux Disease in Infants and Children: from Guidelines to Clinical Practice. Pediatr Gastroenterol Hepatol Nutr. 2019 Mar;22(2):107 - 121

130. Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, Iijima K, Koike T, Omura N, Nomura T, Kawamura O, Ohara S, Ozawa S, Kinoshita Y, Mochida S, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 2022 Apr; 57(4): 267 - 285].

131. Sodikoff J, Hirano I. Proton pump inhibitor-responsive esophageal eosinophilia does not preclude food-responsive eosinophilic esophagitis. J Allergy Clin immunol 2016; 137: 631 - 633

132. Lucendo AJ, Arias A, Gonzalez-Cervera J, et al. Dual response to dietary/topical steroid and proton pump inhibitor therapy in adult patients with eosinophilic esophagitis. J Allergy Clin Immunol 2016; 137: 931 - 934

133. J.M. Spergel Allergy testing in eosinophilic esophagitis. UpToDate. December 2022

134. Cotton CC, Erim D, Eluri S, et al. Cost utility analysis of topical steroids compared with die-tary elimination for treatment of eosinophilic esophagitis. Clin Gastroenterol Hepatol 2017; 15: 841 - 9

135. Kagalwalla A, Amsden K, Makhija MM, et al. A multicenter study assessing the clinical, en-doscopic and histologic response to four food elimination diet for the treatment of eosino-philic esophagitis. Gastroenterology 2015; 148(Suppl 1): S-30].

136. Hirano, E. S. Chan, M. Rank et al. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters Clinical Guidelines for the Management of Eosinophilic Esophagitis. Gastroenterology 2020; 158: 1776 - 1786

137. Khokhar D., Marella S., Idelman G., Chang J.W., Chehade M., Hogan S.P. Eosinophilic esophagitis: Immune mechanisms and therapeutic targets. Clin Exp Allergy. 2022; 52(10): 1142 - 1156.

138. Blanchard C, Stucke EM, Rodriguez Jimenez B, et al. A striking local esophageal cytokine expression profile in eosinophilic esophagitis. J Allergy Clin Immunol. 2011; 127(1): 208 - 217

139. Blanchard C, Stucke EM, Burwinkel K, et al. Coordinate interaction between IL 13 and epithelial differentiation cluster genes in eosinophilic esophagitis. J Immunol. 2010; 184(7): 4033 - 4041.

140. Visaggi P, Ghisa M, Marabotto E, Venturini A, Stefani Donati D, Bellini M, Savarino V, de Bortoli N, Savarino E. Esophageal dysmotility in patients with eosinophilic esophagitis: pathogenesis, assessment tools, manometric characteristics, and clinical implications. Esophagus. 2023 Jan;20(1): 29 - 38.

141. Warners MJ, Vlieg-Boerstra BJ, Verheij J, van Rhijn BD, Van Ampting MT, Harthoorn LF, de Jonge WJ, Smout AJ, Bredenoord AJ. Elemental diet decreases inflammation and improves symptoms in adult eosinophilic oesophagitis patients. Aliment Pharmacol Ther. 2017 Mar; 45(6): 777 - 787. doi: 10.1111/apt.13953. Epub 2017 Jan 23. PMID: 28112427; PMCID: PMC5324627

142. Peterson KA, Boynton KK. Which patients with eosinophilic esophagitis (EoE) should receive elemental diets versus other therapies? Curr Gastroenterol Rep 2014; 16: 364.

143. Groetch M, Venter C, Skypala I, et al. Dietary therapy and nutrition management of eosinophilic esophagitis: a work group report of the American Academy of allergy, asthma, and immunology. J Allergy Clin Immunol 2017; 5: 312 - 24

144. Cianferoni A, Shuker M, Brown-Whitehorn T, et al. Food avoidance strategies in eosinophilic oesophagitis. Clin Exp Allergy 2019; 49: 269 - 284

145. Sova C, Feuling MB, Baumler M, et al. Systematic review of nutrient intake and growth in children with multiple IgE-mediated food allergies. Nutr Clin Pract 2013; 28: 669 - 75.

146. Lucendo AJ, Molina-Infante J. Dietary therapy for eosinophilic esophagitis: chances and limitations in the clinical practice. Expert Rev Gastroenterol Hepatol. 2020 Oct; 14(10): 941 - 952. doi: 10.1080/17474124.2020

147. Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, et al. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. Aliment Pharmacol Ther 2013; 38: 1312 - 1319.

148. Dellon ES, Speck O, Woodward K, et al. Clinical and endoscopic characteristics do not reliably differentiate PPI-responsive esophageal eosinophilia and eosinophilic esophagitis in patients undergoing upper endoscopy: a prospective cohort study. Am J Gastroenterol 2013; 108: 1854 - 1860

149. Franciosi JP, Mougey EB, Dellon ES, Gutierrez-Junquera C, Fernandez-Fernandez S, Venkatesh RD, Gupta SK. Proton Pump Inhibitor Therapy for Eosinophilic Esophagitis: History, Mechanisms, Efficacy, and Future Directions. J Asthma Allergy. 2022 Feb 26; 15: 281 - 302. doi: 10.2147/JAA.S274524. PMID: 35250281; PMCID: PMC8892718

150. , Ferna ndez-Ferna ndez S, Cilleruelo ML, et al. Long-term treatment with proton pump inhibitors is effective in children with eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2018; 67: 210 - 6

151. Aceves SS, Bastian JF, Newbury RO, Dohil R. Oral viscous budesonide: a potential new therapy for eosinophilic esophagitis in children. Am J Gastroenterol. 2007 Oct; 102(10): 2271 - 9; quiz 2280. doi: 10.1111/j.1572-0241.2007.01379.x. Epub 2007 Jun 20. PMID: 17581266

152. Bonis P.A.L., Gupta S.K. Treatment of eosinophilic esophagitis (EoE). UpToDate November 21, 2022

153. Dellon ES, Katzka DA, Collins MH, Hamdani M, Gupta SK, Hirano I; MP-101-06 Investigators. Budesonide Oral Suspension Improves Symptomatic, Endoscopic, and Histologic Parameters Compared With Placebo in Patients With Eosinophilic Esophagitis. Gastroenterology. 2017 Mar; 152(4): 776 - 786. e5. doi: 10.1053/j.gastro.2016.11.021.

154. Hirano I, Collins MH, Katzka DA, Mukkada VA, Falk GW, Morey R, Desai NK, Lan L, Williams J, Dellon ES; ORBIT1/SHP621-301 Investigators. Budesonide Oral Suspension Improves Out-comes in Patients With Eosinophilic Esophagitis: Results from a Phase 3 Trial. Clin Gastroenterol Hepatol. 2022 Mar; 20(3): 525 - 534. e10. doi: 10.1016/j.cgh.2021.04.022. Epub 2021 Apr 19. Erratum in: Clin Gastroenterol Hepatol. 2022 Oct; 20(10): 2418. PMID: 33887475

155. Andreae DA, Hanna MG, Magid MS, et al. Swallowed fluticasone propionate is an effective long-term maintenance therapy for children with eosinophilic esophagitis. Am J Gastroenterol 2016; 111: 1187 - 1197

156. Tomizawa Y, Melek J, Komaki Y, Kavitt RT, Sakuraba A. Efficacy of Pharmacologic Therapy for Eosinophilic Esophagitis: A Systematic Review and Network Meta-Analysis. J Clin Gastroenterol. 2018 Aug; 52(7): 596 - 606. doi: 10.1097/MCG.0000000000000878. PMID: 28787360.

157. Dellon ES, Spergel JM. Biologics in eosinophilic gastrointestinal diseases. Ann Allergy Asthma Immunol. 2023 Jan; 130(1): 21 - 27. doi: 10.1016/j.anai.2022.06.015. Epub 2022 Jun 20. PMID: 35738437; PMCID: PMC10191215.

158. Tamarit-Sebastian S, Ferrer-Soler FM, Lucendo AJ. Current options and investigational drugs for the treatment of eosinophilic esophagitis. Expert Opin Investig Drugs. 2022 Feb; 31(2): 193 - 210. doi: 10.1080/13543784.2022.2033207. Epub 2022 Jan 31. PMID: 35072575.

159. Dellon ES, Rothenberg ME, Collins MH, Hirano I, Chehade M, Bredenoord AJ, Lucendo AJ, Spergel JM, Aceves S, Sun X, Kosloski MP, Kamal MA, Hamilton JD, Beazley B, McCann E, Patel K, Mannent LP, Laws E, Akinlade B, Amin N, Lim WK, Wipperman MF, Ruddy M, Patel N, Weinreich DR, Yancopoulos GD, Shumel B, Maloney J, Giannelou A, Shabbir A. Dupilumab in Adults and Adolescents with Eosinophilic Esophagitis. N Engl J Med. 2022 Dec 22; 387(25): 2317 - 2330

160. Marc E. Rothenberg, Evan S. Dellon, Margaret H. Collins, Albert J. Bredenoord, Ikuo Hirano, Kathryn A. Peterson, Laura Brooks, Harald Fjallbrant, Hanna K. Grindebacke, Calvin N. Ho, Matthew Keith, Christopher McCrae, Wendy White, Catherine Datto. EFFICACY AND SAFETY OF BENRALIZUMAB IN ADULTS AND ADOLESCENTS WITH EOSINOPHILIC ESOPHAGITIS: RESULTS FROM THE 24-WEEK DOUBLE-BLIND PERIOD OF THE PHASE 3 MESSINA TRIAL. DDW 2023 Poster.

161. ClinicalTrials.gov Identifier: NCT04543409: A Multicenter, Randomized, Double-blind, Parallel-group, Placebo Controlled Study to Investigate the Use of Benralizumab for Eosinophilic Esophagitis. NCT04543409,A Study of Benralizumab in Patients With Eosinophilic Esophagitis,https://beta.clinicaltrials.gov/study/NCT04543409,Eosinophilic Esophagitis,BIOLOGICAL: Benralizumab|BIOLOGICAL: Matching placebo,AstraZeneca

162. Hudgens S, Evans C, Phillips E, Hill M. Psychometric validation of the Dysphagia Symptom Questionnaire in patients with eosinophilic esophagitis treated with budesonide oral suspension. J Patient Rep Outcomes. 2017; 1(1): 3. doi: 10.1186/s41687-017-0006-5. Epub 2017 Sep 12. PMID: 29757322; PMCID: PMC5934937.

163. Taft TH, Kern E, Kwiatek MA, Hirano I, Gonsalves N, Keefer L. The adult eosinophilic oesophagitis quality of life questionnaire: a new measure of health-related quality of life. Aliment Pharmacol Ther. 2011 Oct; 34(7): 790 - 8.

164. Ma, C.; Bredenoord, A.J.; Dellon, E.S.; Alexander, J.A.; Biedermann, L.; Hogan, M.; Guizzetti, L.; Zou, G.; Katzka, D.A.; Chehade, M.; et al. Reliability and Responsiveness of Endoscopic Disease Activity Assessment in Eosinophilic Esophagitis. Gastrointest. Endosc. 2022, 95, 1126 - 1137. e2.

165. Thel HL, Anderson C, Xue AZ, Jensen ET, Dellon ES. Prevalence and Costs of Eosinophilic Esophagitis in the United States. Clin Gastroenterol Hepatol. 2025 Feb; 23(2): 272 - 280. e8. doi: 10.1016/j.cgh.2024.09.031.

166. Dellon ES, Muir AB, Katzka DA, Shah SC, Sauer BG, Aceves SS, Furuta GT, Gonsalves N, Hirano I. ACG Clinical Guideline: Diagnosis and Management of Eosinophilic Esophagitis. Am J Gastroenterol. 2025 Jan 1; 120(1): 31 - 59. doi: 10.14309/ajg.0000000000003194. Epub 2025 Jan 2. PMID: 39745304.

167. Amil-Dias J, Oliva S, Papadopoulou A, Thomson M, Guti rrez-Junquera C, Kalach N, Orel R, Auth MK, Nijenhuis-Hendriks D, Strisciuglio C, Bauraind O, Chong S, Ortega GD, F rnandez SF, Furman M, Garcia-Puig R, Gottrand F, Homan M, Huysentruyt K, Kostovski A, Otte S, Rea F, Roma E, Romano C, Tzivinikos C, Urbonas V, Velde SV, Zangen T, Zevit N. Diagnosis and management of eosinophilic esophagitis in children: An update from the European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN). J Pediatr Gastroenterol Nutr. 2024 Aug; 79(2): 394 - 437. doi: 10.1002/jpn3.12188. Epub 2024 Jun 24. PMID: 38923067.

168. Oliva S, Arrigo S, Bramuzzo M, Cisar F, Dabizzi E, Di Nardo G, Gandullia P, Martinelli M, Mennini M, Monica F, Norsa L, Rea F, Renzo S, Romano C, Salvatore S, Savarino EV, Strisciuglio C, Tambucci R, Calabrese C, De Angelis P; Italian Society of Pediatric Gastroen-terology Hepatology and Nutrition (SIGENP), The Italian Association of Hospital Gastroen-terologists and Endoscopists (AIGO), The Italian Society of Gastroenterology (SIGE), and The Italian Society of Digestive Endoscopy (SIED). Eosinophilic esophagitis in children and adolescents: a clinical practice guideline. Ital J Pediatr. 2025 Jul 23; 51(1): 242. doi: 10.1186/s13052-025-02056-x. PMID: 40702503; PMCID: PMC12288368.

169. Mayerhofer C., Kavallar A.M., Aldrian D., Lindner A.K., M ller T., Vogel G.F. Efficacy of Elimination Diets in Eosinophilic Esophagitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2023; 21(9): 2197 - 2210. e3. https://doi.org/10.1016/j.cgh.2023.01.019

170. Cotton C.C., Eluri S., Wolf W.A., Dellon E.S. Six-Food Elimination Diet and Topical Ster-oids are Effective for Eosinophilic Esophagitis: A Meta-Regression. Dig Dis Sci. 2017; 62(9): 2408 - 2420. https://doi.org/10.1007/s10620-017-4642-7

171. , , , Molina-Infante J., Lucendo A.J. Efficacy of Dietary Therapy for Eosinophilic Esophagitis in Children and Adults: An Updated Sys-tematic Review and Meta-Analysis. Nutrients. 2024; 16(14): 2231. https://doi.org/10.3390/nu16142231

172. Кайбышева, В. О. Лечение эозинофильного эзофагита: обзор литературы и описание собственных клинических наблюдений / В. О. Кайбышева, Е. Д. Федоров, С. Г. Ша-повальянц // Российский аллергологический журнал. - 2025. - Т. 22, N 1. - С. 23 - 43. - DOI 10.36691/RJA17001. - EDN KGCPXZ.

173. Wechsler J.B., Schwartz S., Arva N.C., Kim K.A., Chen L., Makhija M., et al. A Single-Food Milk Elimination Diet Is Effective for Treatment of Eosinophilic Esophagitis in Children. Clin Gastroenterol Hepatol. 2022 Aug; 20(8): 1748 - 1756. e11. https://doi.org/10.1016/j.cgh.2021.03.049

174. Chehade M. et al. Dupilumab for Eosinophilic Esophagitis in Patients 1 to 11 Years of Age. N Engl J Med. 2024 Jun 27; 390(24): 2239 - 2251. doi: 10.1056/NEJMoa2312282. PMID: 38924731

175. Kerlin P, Jones D, Remedios M, Campbell C. Prevalence of eosinophilic esophagitis in adults with food bolus obstruction of the esophagus. J Clin Gastroenterol. 2007; 41: 356 - 361.

176. Byrne KR, Panagiotakis PH, Hilden K, Thomas KL, Peterson KA, Fang JC. Retrospective Analysis of Esophageal Food Impaction: Differences in Etiology by Age and Gender. Dig Dis Sci. 2007.

177. Kirchner GI, Zuber-Jerger I, Endlicher E, Gelbmann C, Ott C, Ruemmele P, Scholmerich J, Klebl F. Causes of bolus impaction in the esophagus. Surg Endosc. 2011; 25: 3170 - 3174. https://doi.org/10.1007/s00464-011-1681-6

178. Sperry SL, Crockett SD, Miller CB, Shaheen NJ, Dellon ES. Esophageal foreign-body impac-tions: epidemiology, time trends, and the impact of the increasing prevalence of eosinophilic esophagitis. Gastrointest Endosc. 2011; 74: 985 - 991. https://doi.org/10.1016/j.gie.2011.06.029

179. Hurtado CW, Furuta GT, Kramer RE. Etiology of esophageal food impactions in children. J Pediatr Gastroenterol Nutr. 2011; 52: 43 - 46. https://doi.org/10.1097/MPG.0b013e3181e67072

180. Diniz LO, Towbin AJ. Causes of Esophageal Food Bolus Impaction in the Pediatric Popula-tion. Dig Dis Sci. 2011. https://doi.org/10.1007/s10620-011-1911-8 65. Mahesh VN, Hol-loway RH, Nguyen NQ. Changing epidemiology of food bolus impaction: is eosinophilic esophagitis to blame? J Gastroenterol Hepatol. 2013; 28: 963 - 966. https://doi.org/10.1111/jgh.12135

181. Heerasing N, Lee SY, Alexander S, Dowling D. Prevalence of eosinophilic oesophagitis in adults presenting with oesophageal food bolus obstruction. World J Gastrointest Pharmacol Ther 2015;6:244 - 247.https://doi.org/10.4292%2Fwjgpt.v6.i4.244

182. Philpott H, Nandurkar S, Thien F, Bloom S, Lin E, Goldberg R, Boyapati R, Finch A, Royce SG, Gibson PR. Seasonal Recurrence of Food Bolus Obstruction in Eosinophilic Esophagitis. Intern Med J. 2015; 45: 939 - 943. https://doi.org/10.1111/imj.12790

183. Hiremath GS, Hameed F, Pacheco A, Olive A, Davis CM, Shulman RJ. Esophageal Food impaction and eosinophilic esophagitis: a retrospective study, systematic review, and metaa-nalysis. Dig Dis Sci. 2015; 60: 3181 - 3193. https://doi.org/10.1007/s10620-015-3723-8

184. Gretarsdottir HM, Jonasson JG, Bjornsson ES. Etiology and management of esophageal food impaction: a population based study. Scand J Gastroenterol. 2015; 50: 513 - 518. https://doi.org/10.3109/00365521.2014.983159 70. Truskaite K, Dlugosz A. Prevalence of Eosinophilic Esophagitis and Lymphocytic Esophagitis in Adults with Esophageal Food Bo-lus Impaction. Gastroenterol Res Pract. 2016. https://doi.org/10.1155/2016/9303858

185. Jensen ET, Kuhl JT, Martin LJ, Rothenberg ME, Dellon ES. Prenatal, intrapartum, and post-natal factors are associated with pediatric eosinophilic esophagitis. J Allergy Clin Immunol. 2018; 141(1): 214 - 222

186. Dhaliwal J, Tobias V, Sugo E, et al. Eosinophilic esophagitis in children with esophageal atre-sia. Dis Esophagus. 2014; 27(4): 340 - 347

187. Franciosi JP, Hommel KA, Greenberg AB, et al. Development of the pediatric quality of life inventory eosinophilic esophagitis module items: qualitative methods. BMC Gastroenter-ol. 2012; 12(12): 135

188. Cotton CC, Woosley JT, Moist SE, et al. Determination of a treatment response threshold for the eosinophilic esophagitis endoscopic reference score. Endoscopy. 2022; 54(7): 635 - 643